IMUX — Immunic, Inc.
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Select
- Employees: 91
- Website: https://imux.com
Latest SEC filings for IMUX
- S-8 — 2026-10-01
- 8-K — 2026-09-11
- 8-K — 2026-09-09
- SCHEDULE 13G — 2026-08-14
- 10-Q — 2026-08-11
- 8-K — 2026-08-11
- 8-K — 2026-07-14
- 8-K — 2026-07-06
- 8-K — 2026-06-29
- 8-K — 2026-05-28
Latest IMUX news
- — New Strong Buy Stocks for October 22nd (Zacks Investment Research)
- — Immunic to present four vidofludimus calcium abstracts at MSToronto2026 (proactiveinvestors.com)
- — Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting (prnewswire.com)
Educational tool only — not investment advice.